Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi.

This research evaluates the combined effect of two drugs, tiotropium and olodaterol, on horse bronchi, hypothesising that the findings could inform strategies for treating human chronic pulmonary conditions. The study finds that the two drugs, when used together, synergistically inhibit bronchial contractility more effectively than when used separately.

Research Context

• Chronic obstructive pulmonary disorders, such as asthma and chronic obstructive pulmonary disease (COPD), adversely affect millions of people worldwide. Current treatment methodologies frequently include the use of long-acting muscarinic antagonist (LAMA) and long-acting β-agonist (LABA) medicines.
• In this study, the researchers focus on two drugs – a LAMA called tiotropium and a LABA called olodaterol. These drugs are often used in fixed-dose combinations (FDC) for patients, but their interaction was not thoroughly reviewed.
• The aim of this study was to understand how these drugs, when administered together, affect equine bronchial contractility as a model for human chronic pulmonary disorders.

Methodology

• The researchers gave the drugs individually and combined at a fixed ratio designed to replicate the concentration of the drug combination currently available (5:5 ratio).
• The effect was then evaluated, focusing on the bronchial contractility or the tightness of the airways that results from parasympathetic activation.
• The drug interaction was analysed using the Bliss Independence and Unified Theory models, commonly used in pharmaceutical studies to quantify the effect of drug combinations.

Findings

• Both tiotropium and olodaterol were found to induce a sub-maximal concentration-dependent reduction in bronchial contractility. However, when combined, the drugs resulted in a complete inhibition of the contractility – more than the effect of each drug administered alone.
• Further analysis suggested a synergistic interaction of the drugs, meaning that their combined effect was more than additive and actually multiplied results.
• This synergistic interaction was even evident when the drugs were administered at low concentrations, providing a more significant effect than anticipated based on the additive effect of both drugs separately.

Implications

• The combination of tiotropium and olodaterol was seen to have a greater impact on blocking bronchial contractility than either of the drugs in isolation, suggesting a potentially effective treatment strategy for chronic pulmonary disorders.
• This study supports the use of LABA/LABA FDC, suggesting they might be effective in delivering tiotropium/olodaterol combination into the lung, inducing a superior synergistic effect.